Aethlon Medical Q2 fiscal 2025: operating loss narrows to $1.5M, clinical trial advances

AETHLON MEDICAL INC

2026-Q2 EPS reported -$10.65

Cash balance $5.8M at Sept 30, 2025; operating expenses down 48% YoY to $1.5M.
Operating loss narrowed to $1.5M from $2.8M in the prior-year quarter.
Nasdaq compliance resolved; AEMD remains listed on the Capital Market.
Recruitment began for Cohort 2 of Australian Hemopurifier oncology trial with pembrolizumab/nivolumab.
Long COVID research with UCSF continues; manuscript in preparation for peer-reviewed journal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.